Pet Cancer Therapeutics Market Size, Share, and Growth Forecast 2026 - 2033

The global pet cancer therapeutics market size is expected to be valued at US$ 493.3 million in 2026 and projected to reach US$ 921.2 million by 2033, growing at a CAGR of 9.3% between 2026 and 2033.

Market expansion is driven by the rising prevalence of cancer in companion animals, increasing willingness of pet owners to pursue advanced treatments, and rapid innovation in veterinary oncology, including immunotherapy and targeted therapies.

The Veterinary Cancer Society and pet cancer charities report that cancer is a leading cause of death in companion animals, accounting for roughly 47% of deaths in dogs (especially over 10 years of age) and about 32% of deaths in cats, which underscores a large and growing therapeutic need. Academic studies in veterinary journals further confirm that the incidence of tumors in dogs and cats is increasing, with mammary, skin, and lymphoid malignancies among the most frequent neoplasms, directly supporting sustained demand for chemotherapy, radiation, and emerging biologic therapies.

Drivers - High and rising burden of cancer in companion animals

Cancer is widely recognized as one of the most common causes of death in dogs and cats in developed countries, creating strong structural demand for effective pet cancer therapeutics. The Veterinary Cancer Society estimates that cancer is responsible for approximately 47% of deaths in dogs particularly those older than 10 years-and around 32% of deaths in cats, while epidemiological reviews show that dogs develop cancer at roughly the same rate as humans. Recent registry-based studies and retrospective analyses from Europe and North America highlight increasing incidence rates for common canine tumors such as lymphoma, mast cell tumors, and mammary tumors, reflecting both longer pet lifespans and greater diagnostic vigilance. As awareness grows among owners and veterinarians, and as pet insurance coverage expands to include oncology, more pets are being staged and treated rather than euthanized at diagnosis, directly fueling demand for chemotherapy agents, radiation protocols, and newer biologic therapies.

Advances in veterinary oncology, including monoclonal antibodies and precision radiation
Another powerful growth driver is the rapid translation of human oncology advances into veterinary medicine, particularly in immunotherapy, monoclonal antibodies, and precision radiation therapy. Companies such as ELIAS Animal Health are actively developing oncolytic virotherapies and personalized immunotherapy platforms for a variety of canine cancers, including osteosarcoma, oral melanoma, lymphoma, and mast cell tumors. Innovative start-ups like Vetigenics are adapting immune checkpoint inhibitors (for example, anti-PD-1 and anti-CTLA-4 monoclonal antibodies) for dogs, with pilot trials in urothelial carcinoma and oral melanoma and regulatory approvals targeted around 2027. On the radiation side, organizations such as PetCure Oncology are pioneering stereotactic radiosurgery (SRS/SRT), while new human-grade stereotactic platforms like Sirius-developed through partnerships between Empyrean Medical Systems and veterinary networks-promise more precise, higher-dose treatments with fewer sessions. These advances expand therapeutic options, improve outcomes, and encourage owners to pursue active treatment.

Restraints - High cost and limited access to advanced oncology care

Despite expanding options, the pet cancer therapeutics market faces significant affordability and access barriers. Advanced treatments such as multi-agent chemotherapy, immunotherapy, and stereotactic radiation can cost several thousand US dollars per treatment course, placing them beyond the reach of many owners without comprehensive pet insurance. Access is also geographically uneven: specialty veterinary oncology centers and radiation facilities are concentrated in major urban hubs or academic institutions, forcing many pet owners to travel long distances or forgo care altogether. Smaller veterinary practices may lack the infrastructure or expertise to safely administer complex chemotherapy protocols or biologics, while concerns about staff exposure to cytotoxic agents can further limit uptake. These economic and logistical constraints dampen the overall addressable market, especially in emerging economies.

Regulatory complexity and translational challenges from human oncology

Development and approval of pet cancer therapeutics involve navigating regulatory pathways overseen by agencies such as the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) and equivalent bodies in Europe and other regions. While human oncology provides a rich source of potential drug candidates, species differences in tumor biology, pharmacokinetics, and immune responses mean that therapies cannot simply be repurposed without dedicated veterinary studies. Designing and funding randomized controlled trials in client-owned pets is challenging and expensive, and some owners are hesitant to enroll their animals in experimental protocols. Moreover, reimbursement mechanisms are limited compared with human medicine, placing more financial burden on owners and making it harder for companies to justify large R&D investments. These factors slow the introduction of novel therapies and can restrict the range of approved indications.

Rapid growth of immunotherapy and targeted therapies for dogs and cats

The fastest-growing therapeutic segment in pet oncology is Immunotherapy, reflecting strong interest in harnessing the host immune system to fight cancer and reduce off-target toxicity. Companies such as ELIAS Animal Health are advancing oncolytic virotherapies and adoptive T-cell protocols (for example, autologous T-cell immunotherapy) for canine osteosarcoma and lymphoma, while emerging firms like Vetigenics are developing species-specific checkpoint inhibitors targeting PD-1 and CTLA-4. Larger animal health players, including Zoetis and Elanco Animal Health, are investing heavily in monoclonal antibody platforms and immunology-focused pipelines, as evidenced by their expansion of antibody manufacturing capacity and strategic focus areas. As clinical data accumulate and regulatory frameworks for veterinary biologics mature, immunotherapies and targeted agents are expected to move from niche applications toward more routine oncology care, offering substantial upside for innovators.

Expanding cancer care infrastructure and tele-oncology services

There is a growing opportunity to broaden access to pet cancer therapeutics by expanding oncology infrastructure and leveraging technology-enabled care models. Networks such as PetCure Oncology already operate multiple specialized radiation centers across the United States, providing stereotactic radiosurgery and comprehensive oncology services in collaboration with local veterinary practices. New initiatives, like the deployment of human-grade stereotactic radiation platforms (for example, Sirius) through partnerships between technology firms and large hospital networks such as Thrive Pet Healthcare, indicate continued investment in cutting-edge cancer care capacity. At the same time, tele-oncology and virtual consultation services allow board-certified veterinary oncologists to support general practitioners and pet owners remotely, improving case selection, treatment planning, and follow-up in regions without specialists. These trends create openings for drug manufacturers to collaborate closely with oncology networks and digital health providers to integrate therapeutics into standardized treatment pathways.

Therapy Type Insights

Within Therapy Type, Chemotherapy remains the leading segment, accounting for an estimated 42% of the pet cancer therapeutics market share in 2025. Conventional cytotoxic chemotherapy has been the backbone of veterinary oncology for decades, with protocols such as CHOP regimens widely used for canine and feline lymphoma and other high-grade malignancies. Chemotherapy drugs are relatively more accessible and familiar to veterinarians compared with newer modalities, and many agents are available as generics adapted from human oncology, enabling broader global use despite cost considerations. Clinical experience and published outcome data support their use across a wide variety of tumor types, from lymphoma and mast cell tumors to osteosarcoma and mammary carcinomas. While targeted therapies, radiation, and immunotherapies are growing rapidly, the established clinical role, guideline inclusion, and relatively widespread availability of chemotherapy keep it as the dominant therapy type in the current market.

Animal Type Insights

In the animal type category, dogs represent the leading segment in 2025, capturing the majority share of the pet cancer therapeutics market. Multiple epidemiologic studies and insurance database analyses confirm that dogs experience cancer at rates comparable to or higher than humans, and that cancer is a leading cause of death in many dog breeds. A large white paper by Nationwide Insurance, covering 1.6 million insured dogs, found that purebred animals had 1.9 times the relative risk of cancer claims compared with mixed breeds, with breeds such as Boxers, Beagles, and Golden Retrievers showing particularly high cancer risk. Companion dog owners are also more likely to seek advanced diagnostics and interventions, supported by rising pet insurance penetration and a strong cultural emphasis on dogs as family members. Together, these factors translate into higher utilization of diagnostics, chemotherapy, radiation, and emerging biologics in dogs versus cats or other companion animals.

Cancer Type Insights

Across cancer type, lymphoma is the leading segment, reflecting its high prevalence and the relatively well-defined treatment protocols available in veterinary oncology. Canine lymphoma is one of the most commonly diagnosed malignancies in dogs worldwide, and feline lymphoma is also highly prevalent, particularly in older cats and certain anatomic forms. Registry-based studies and hospital case series consistently identify lymphoid neoplasms among the top tumor types, alongside mast cell tumors, mammary tumors, and skin cancers. Importantly, lymphoma is often considered a systemic disease that responds favorably to multi-agent chemotherapy protocols, making it a major focus for both existing chemotherapeutic regimens and newer targeted or immunotherapeutic approaches. As a result, a substantial proportion of veterinary oncology clinical trials, practice guidelines, and commercial therapies are directed toward lymphoma, reinforcing its position as the dominant cancer type segment.

Distribution Channel Analysis

In the distribution channel, veterinary hospitals & clinics constitute the leading segment in 2025, as most pet cancer therapeutics are prescribed, administered, and monitored through clinical settings rather than over-the-counter channels. Complex treatments such as intravenous chemotherapy, radiation therapy, and advanced immunotherapies require specialized equipment, trained staff, and close patient monitoring, which are typically available only in veterinary hospitals, specialty referral centers, and oncology clinics. Even for oral chemotherapeutics or targeted agents dispensed for home administration, veterinarians remain the primary decision-makers and gatekeepers, determining eligibility, dosing, and follow-up schedules. The central role of hospitals and clinics in staging, diagnostics (for example, imaging and histopathology), and multidisciplinary care planning further concentrates therapeutic use within this channel. While online and retail pharmacies play an important role in maintenance medications and supportive care, high-acuity oncology treatments remain anchored in the Veterinary Hospitals & Clinics segment.

North America Pet Cancer Therapeutics Market Trends and Insights

North America is the leading regional market for pet cancer therapeutics, with an estimated 43% share of global revenues in 2025, underpinned by high pet ownership, strong expenditure on veterinary care, and advanced oncology infrastructure. The United States in particular has a well-developed ecosystem of board-certified veterinary oncologists, academic teaching hospitals, and private specialty networks such as PetCure Oncology and Thrive Pet Healthcare, which offer chemotherapy, surgery, and advanced radiation modalities including stereotactic radiosurgery. High awareness of pet cancer, coupled with widespread availability of pet insurance, encourages owners to pursue sophisticated and often costly treatments rather than opting solely for palliative care.

Regulatory frameworks overseen by FDA-CVM and other agencies support the development and approval of novel cancer therapeutics, including monoclonal antibodies, oncolytic viruses, and small-molecule targeted agents. Major animal health companies headquartered or strongly active in North America-such as Zoetis, Elanco Animal Health, Merck Animal Health, and Boehringer Ingelheim Animal Health-are investing in oncology pipelines, biologics manufacturing capacity, and clinical trials in client-owned pets, further strengthening the innovation ecosystem. As human–animal bond trends deepen and spending on pet health continues to rise, North America is expected to maintain leadership in both adoption of new therapies and contribution to global veterinary oncology research.

Asia Pacific Pet Cancer Therapeutics Market Trends and Insights

The Asia Pacific region is the fastest-growing market for pet cancer therapeutics, supported by rising companion animal ownership, urbanization, and a rapidly expanding middle class in countries such as China, Japan, India, and key ASEAN markets. Pet populations and veterinary service utilization are increasing quickly, and cancer is gaining recognition as a significant health issue for aging dogs and cats, as in Western markets. Japan, with one of the world’s oldest companion animal populations, has a particularly high prevalence of age-associated diseases, including neoplasia, and a sophisticated veterinary infrastructure that supports advanced oncology care.

China and India are investing in veterinary education, specialty hospitals, and diagnostic laboratories, creating a foundation for broader adoption of chemotherapy, surgery, and, gradually, immunotherapies and radiation. As multinational animal health companies expand their presence and local players develop regionally tailored cancer therapies, Asia Pacific is expected to see strong growth in veterinary oncology revenues. Additionally, cost advantages in clinical research and biologics manufacturing may encourage global firms to conduct studies and establish production hubs in this region, further reinforcing its status as the fastest-growing market segment over the 2025-2032 period.

The pet cancer therapeutics market is moderately consolidated at the top, with large multinational animal health companies and a growing cohort of specialized oncology biotech firms. Major players such as Zoetis, Elanco Animal Health, Boehringer Ingelheim, Merck Animal Health, Virbac, Ceva Santé Animale, and Vetoquinol leverage extensive R&D capabilities, global distribution networks, and broad portfolios to compete across multiple therapeutic categories. At the same time, innovative smaller companies-including AB Science, Anivive Lifesciences, ELIAS Animal Health, VetDC, and PetCure Oncology-are focused on niche oncology assets such as tyrosine kinase inhibitors, immunotherapies, and stereotactic radiation services. Key differentiators include depth of oncology pipelines, biologics manufacturing expertise, partnerships with academic centers, and integrated service models that combine therapeutics with advanced diagnostics and radiation platforms.

Key Developments:

• In October 2025, Akston Biosciences Corporation announced the launch of a clinical trial for a novel canine cancer therapy in collaboration with Purdue University College of Veterinary Medicine. The study evaluated a first-in-class immuno-enhancing therapy developed using Akston’s proprietary Fc-fusion protein platform and designed as an intramuscular injection targeting the PD-L1 protein in dogs with solid tumors.
• In June 2025, Vetigenics launched the CHECKMATE K9 pilot clinical study and dosed the first canine patient at the University of Wisconsin. The study evaluated a dual immune checkpoint inhibitor therapy combining VGS-001 (anti-cCTLA-4 monoclonal antibody) and VGS-002 (anti-cPD-1 monoclonal antibody) for the treatment of dogs with various solid tumors.
• In November 2025, Thrive Pet Healthcare partnered with Empyrean Medical Systems to introduce the Sirius™ advanced radiation platform to veterinary oncology. Through this collaboration, the companies planned to deploy the first system at PetCure Oncology located at the Veterinary Specialty Center of Seattle, expected to open in early 2026